Hospira recalls two lots of naloxone hydrochloride injection

Hospira announced the voluntary recall of two lots of naloxone hydrochloride injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL, Carpuject Single-use cartridge syringe system. The recall was initiated because of "the potential presence of embedded and loose particulate matter on the syringe plunger," FDA said Monday.

Hospira announced the voluntary recall of two lots of naloxone hydrochloride injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL, Carpuject Single-use cartridge syringe system. The recall was initiated because of "the potential presence of embedded and loose particulate matter on the syringe plunger," FDA said Monday. Hospira said it has not yet received any reports of adverse events related to this issue. Additional information about the recall is available <a href="https://www.fda.gov/Safety/Recalls/ucm609668.htm&quot; target="_blank">here</a>.